



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 29 Aug 2016 (#29)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov).

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa Coetsee [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.**

## Important notices

- Notice of Pre-application Webinar for PAR-16-105 "Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (U01)" ([NOT-CA-16-066](#))
- Request for Information: Epidemiology Research on Novel Infectious Agents and Cancer Occurrence and Outcomes ([NOT-CA-16-067](#))

### 1. BRAIN Initiative: Non-Invasive Neuromodulation - New Tools and Techniques for Spatiotemporal Precision

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** ([RFA-MH-17-240](#))

**Type:** R01

**Application Due Date:** November 23, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

**Purpose:** This Funding Opportunity Announcement (FOA) solicits grant applications in two related but distinct areas. The first area is in the development and testing of novel tools and methods of neuromodulation that go beyond the existing variations on magnetic or electrical stimulation, and that represent more than an incremental advance over existing approaches. The second distinct area that this FOA seeks to encourage is the optimization of existing electrical and magnetic stimulation methods.

**Budget:** Issuing IC and partner components intend to commit an estimated total of \$3 million to fund approximately 5 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

### 2. BRAIN Initiative: Non-Invasive Neuromodulation - Mechanisms and Dose/Response Relationships for Targeted CNS Effects

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** ([RFA-MH-17-245](#))

**Type:** R01

**Application Due Date:** Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

**Purpose:** The focus of this Funding Opportunity Announcement (FOA) is to better understand how existing non-invasive neuromodulation devices affect brain circuitry. This information should shed light on dose/response relationships that could be used for neuroscience applications and clinical interventions.

**Budget:** Issuing IC and partner components intend to commit an estimated total of \$ 2.3 million to fund approximately 4 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

### 3. NCI Small Grants Program for Cancer Research

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** ([PAR-16-416](#))

**Type:** R03

**Application Due Date:** February 28, 2017; June 27, 2017; October 26, 2017; February 27, 2018; June 29, 2018; October 26, 2018; February 26, 2019; June 28, 2019; October 25, 2019. **AIDS dates:** May 7, 2017; September 7, 2017; January 7, 2018; May 7, 2018; September 7, 2018; January 7, 2019; May 7, 2019; September 7, 2019; January 7, 2020. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

**Purpose:** This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

**Budget:** A budget for direct costs of up to \$50,000 per year may be requested. The maximum project period is 2 years.

[Brief definitions of some NIH grant mechanisms:](#) [comprehensive list of extramural grant and cooperative agreement activity codes](#)

**D71 - International Research Training Planning Grant:** To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

**D43 - International Research Training Grants:** To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

**R01 – NIH Research Project Grant Program:** most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

**R21 – NIH Exploratory/Developmental Research Grant:** encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

**R03 – NIH Small Grant Program:** limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

**R21/R33 - Phased Innovation:** The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

**R25 – NIH Education Projects:** used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

**R34 - Clinical Trial Planning Grant Program:** To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

**R35 - Outstanding Investigator Award:** To provide long term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential.

**U01 – NIH Research Project Cooperative Agreement:** supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

**U24 – Resource-Related Research Projects – Cooperative Agreements:** To support research projects contributing to improvement of the capability of resources to serve biomedical research.

**U01 – NIH Research Project Cooperative Agreement:** supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

**U19 - Research Program-Cooperative Agreements:** supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

**Glossary of selected acronyms:**

**FOA** Funding Opportunity Announcement

**PA** Program Announcements (*click on “PA” to search for further funding opportunities*)

**RFA** Request for Applications (*click on “RFA” to search for further funding opportunities*)

Complete [Glossary and acronym list of NIH Terms](#)

